The University of Southampton
University of Southampton Institutional Repository

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

Pardanani, Animesh, Reeder, Terra, Porrata, Luis F., Li, Chin-Yang, Tazelaar, Henry D., Baxter, E. Joanna, Witzig, Thomas E., Cross, Nicholas C.P. and Tefferi, Ayalew (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders Blood, 101, (9), pp. 3391-3397. (doi:10.1182/blood-2002-10-3103).

Record type: Article


Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality. In the current study, we sought to confirm the preliminary observations in HES as well as evaluate the therapeutic value of imatinib in eos-CMD that is not associated with t(5;12)(q33;p13). Five patients with HES (all men, median age = 46 years) and 2 with eos-CMD (both men, aged 45 and 58 years) were treated with imatinib at a starting dose of 100 to 400 mg/day. Cytogenetic studies showed no evidence of either the bcr-abl translocation or t(5;12)(q33;p13) in any patient. Screening of exons encoding the intracellular catalytic domains and extracellular ligand binding domains of PDGFR (exons 2-23) and c-kit (exons 1-21) in 6 patients demonstrated mostly previously known polymorphisms. At a median follow-up of 17 weeks (range, 10-33 weeks), 2 patients with HES and 1 with eos-CMD have achieved complete clinical remission and 1 additional patient with HES has achieved a partial remission. In contrast to previous observations, all 4 responding patients had elevated serum interleukin-5 levels. Although the drug was well tolerated in most patients, a previously unrecognized treatment toxicity of acute left ventricular dysfunction occurred in a responding patient with HES within the first week of treatment. Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy.

Full text not available from this repository.

More information

Published date: 2003
Additional Information: clinical observations, interventions and therapeutic trials


Local EPrints ID: 24893
ISSN: 0006-4971
PURE UUID: 598a0d1a-687f-41f4-a86d-7f3a70b8f039
ORCID for Nicholas C.P. Cross: ORCID iD

Catalogue record

Date deposited: 04 Apr 2006
Last modified: 17 Jul 2017 16:12

Export record



Author: Animesh Pardanani
Author: Terra Reeder
Author: Luis F. Porrata
Author: Chin-Yang Li
Author: Henry D. Tazelaar
Author: E. Joanna Baxter
Author: Thomas E. Witzig
Author: Ayalew Tefferi

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.